RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04905056, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 85 years; sex: all

    Registered eligibility fields

  2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);

    Inclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04905056, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged between 18 and 85 years;
  • GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);
  • The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm;
  • For single GGO: obvious progress was observed in pure GGO or the solid component of mixed ground glass nodules was more than or equal to 2 mm
  • The patients were unable to tolerate the operation for various reasons or multiple grinding glass nodules, operation can not be completely removed; or patients had received surgery in ipsilateral chest
  • The patient is able to understand and comply with the study and has provided written informed consent

Exclusion Criteria:

  • Patients who participated in any drug and / or medical device clinical trials within one month before the trial
  • had severe disease conditions
  • allergy to narcotic drugs
  • had other autoimmune disease
  • dementia or cognitive impairment can't cooperate with researchers
  • any local treatment other than ablation was received within 4 weeks before the study

Quoted from ClinicalTrials.gov, NCT04905056, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04905056, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04905056